DYN 12, a small molecule inhibitor of the enzyme amadorase, lowers plasma 3-deoxyglucosone levels in diabetic rats

Diabetes Technology and Therapeutics

Volumn 3, Issue 4, 2001, Pages 609-616

  Kappler, Francis ^a   Schwartz, Michael L ^a   Su, Bangying ^a   Tobia, Annette M ^a   Brown, Truman ^a  

^a Dynamis Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; AMADORASE; CARBONYL DERIVATIVE; DYN 12; ENZYME INHIBITOR; FRUCTOSAMINE; LINK PROTEIN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENZYME ANALYSIS; ENZYME ISOLATION; ENZYME PURIFICATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RAT;

AMINO ACID OXIDOREDUCTASES; ANIMALS; DEOXYGLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY GLOMERULUS; ORGANIC CHEMICALS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RATS; REFERENCE VALUES;

EID: 0035724697     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/15209150152811234     Document Type: Article

References (33)

1. Novel inhibitors of advanced glycation endproducts
2. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept
3. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress
4. Advanced glycation: An important pathological event in diabetic and age-related ocular disease
5. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas
6. Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. A possible participation of advanced glycation end products in the development of the early phase of diabetic retinopathy
7. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
8. VEGF localisation in diabetic retinopathy
9. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster
10. Advanced glycation end products increase retinal vascular endothelial growth factor expression
11. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
12. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells
13. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy
14. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
15. EF6555, a novel AGE production inhibitor, prevents progression of diabetic nephropathy in STZ-induced rats
16. Advanced glycosylation end products in patients with diabetic nephropathy
17. Nonenzymatic glucosylation of lysine residues in albumin
18. 3-Deoxyglucosone, an intermediate product of the Maillard reaction
19. Lilly lecture 1993. Glycation and diabetic complications
20. Hemoglobin-AGE: A circulating marker of advanced glycosylation
21. Enzymatic production of 3-deoxyglucosone
22. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo
23. Presence of 3-deoxyglucosone, a potent protein crosslinking intermediate of Maillard reaction, in diabetic serum
24. 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes
25. Metabolism of fructose-3-phosphate in the diabetic rat lens
26. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
27. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
28. Teratogenicity of 3-deoxyglucosone and diabetic embryopathy
29. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus
30. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat
31. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats
32. Identification of fructose 3-phosphate in the lens of diabetic rats
33. Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase